TapewireFind a company

person · Reporting owner

Dake Benjamin T

Disclosed activity across 1 company

Tapewire entity
88536
SEC CIK
0001869248

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Jade Biosciences, Inc.AVTE · Entity 4757SEE REMARKSJuly 31, 2024August 02, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Jade Biosciences, Inc.

Report date July 31, 2024 · Filed August 02, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect14,252 Ending reported balance After 2024-08-01 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2024-07-31 · Exercise / conversion · Acquired 11,454 · Balance 12,745

Row 2 · 2024-08-01 · Exercise / conversion · Acquired 1,507 · Balance 14,252

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03Direct0 Reported balance After 2024-07-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-07-31 · Exercise / conversion · Disposed 906 · Balance 0

F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03Direct1,507 Reported balance After 2024-07-31 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2024-07-31 · Exercise / conversion · Disposed 10,548 · Balance 1,507

F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03Direct0 Reported balance After 2024-08-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2024-08-01 · Exercise / conversion · Disposed 1,507 · Balance 0

F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 01, 2024 Filed Aug 2, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,507 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-24-020662 · form4-08022024_060818.xml · derivative · entry 5

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,507 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
August 01, 2024 Filed Aug 2, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 1,507 $1.74 $2,622.18
Disclosure

SEC source: 0001415889-24-020662 · form4-08022024_060818.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,252

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2024 Filed Aug 2, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 10,548 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-24-020662 · form4-08022024_060818.xml · derivative · entry 4

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,507

Underlying: Common Stock · 10,548 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
July 31, 2024 Filed Aug 2, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 906 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-24-020662 · form4-08022024_060818.xml · derivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 906 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
July 31, 2024 Filed Aug 2, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 11,454 $1.74 $19,929.96
Disclosure

SEC source: 0001415889-24-020662 · form4-08022024_060818.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,745

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 17, 2024 Filed Apr 19, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 6,853 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-24-011252 · form4-04192024_060407.xml · derivative · entry 5

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,936

Underlying: Common Stock · 6,853 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

F4 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
April 17, 2024 Filed Apr 19, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 68 $23.97 $1,629.96
Disclosure

SEC source: 0001415889-24-011252 · form4-04192024_060407.xml · nonDerivative · entry 4

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

Read SEC document
April 17, 2024 Filed Apr 19, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 338 $23.17 $7,831.43
Disclosure

SEC source: 0001415889-24-011252 · form4-04192024_060407.xml · nonDerivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,359

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.825 to $23.65, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
April 17, 2024 Filed Apr 19, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 6,447 $22.32 $143,865.45
Disclosure

SEC source: 0001415889-24-011252 · form4-04192024_060407.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,697

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.812 to $22.80, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
April 17, 2024 Filed Apr 19, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 6,853 $2.14 $14,665.42
Disclosure

SEC source: 0001415889-24-011252 · form4-04192024_060407.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,144

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 3,325 $0.00 Strike: $10.61 $0.00
Disclosure

SEC source: 0001415889-24-010137 · form4-04032024_060406.xml · derivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,675

Underlying: Common Stock · 3,325 shares

Expires 2031-12-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

F3 · derivative.exercise_date: A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 3,325 $31.97 $106,316.54
Disclosure

SEC source: 0001415889-24-010137 · form4-04032024_060406.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.95 to $32.415, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 3,325 $10.61 $35,278.25
Disclosure

SEC source: 0001415889-24-010137 · form4-04032024_060406.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,616

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

Read SEC document
March 27, 2024 Filed Mar 28, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 11,068 $0.00 Strike: $10.61 $0.00
Disclosure

SEC source: 0001415889-24-009364 · form4-03282024_060301.xml · derivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,000

Underlying: Common Stock · 11,068 shares

Expires 2031-12-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

F3 · derivative.exercise_date: A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
March 27, 2024 Filed Mar 28, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 11,068 $27.97 $309,518.83
Disclosure

SEC source: 0001415889-24-009364 · form4-03282024_060301.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.95 to $28.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
March 27, 2024 Filed Mar 28, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 11,068 $10.61 $117,431.48
Disclosure

SEC source: 0001415889-24-009364 · form4-03282024_060301.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,359

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

Read SEC document
March 25, 2024 Filed Mar 27, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 3,432 $0.00 Strike: $10.61 $0.00
Disclosure

SEC source: 0001415889-24-009243 · form4-03272024_060301.xml · derivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,068

Underlying: Common Stock · 3,432 shares

Expires 2031-12-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

F3 · derivative.exercise_date: A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
March 25, 2024 Filed Mar 27, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 3,432 $28.01 $96,119.34
Disclosure

SEC source: 0001415889-24-009243 · form4-03272024_060301.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.95 to $28.385, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
March 25, 2024 Filed Mar 27, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 3,432 $10.61 $36,413.52
Disclosure

SEC source: 0001415889-24-009243 · form4-03272024_060301.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,723

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

Read SEC document
March 18, 2024 Filed Mar 20, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 14,500 $0.00 Strike: $10.61 $0.00
Disclosure

SEC source: 0001415889-24-008770 · form4-03202024_060307.xml · derivative · entry 6

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,500

Underlying: Common Stock · 14,500 shares

Expires 2031-12-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

F5 · derivative.exercise_date: A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
March 18, 2024 Filed Mar 20, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 20,557 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-24-008770 · form4-03202024_060307.xml · derivative · entry 5

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,789

Underlying: Common Stock · 20,557 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

F4 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
March 18, 2024 Filed Mar 20, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 7,581 $26.48 $200,763.83
Disclosure

SEC source: 0001415889-24-008770 · form4-03202024_060307.xml · nonDerivative · entry 4

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.25 to $26.88, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
March 18, 2024 Filed Mar 20, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 27,476 $25.74 $707,281.70
Disclosure

SEC source: 0001415889-24-008770 · form4-03202024_060307.xml · nonDerivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,872

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.235 to $26.234, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
March 18, 2024 Filed Mar 20, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 14,500 $10.61 $153,845.00
Disclosure

SEC source: 0001415889-24-008770 · form4-03202024_060307.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

Read SEC document
March 18, 2024 Filed Mar 20, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 20,557 $2.14 $43,991.98
Disclosure

SEC source: 0001415889-24-008770 · form4-03202024_060307.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,848

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.

Read SEC document
January 22, 2024 Filed Jan 24, 2024 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 GrantStock Options (Right to Buy) · Derivative 66,586 $0.00 Strike: $20.00 $0.00
Disclosure

SEC source: 0001415889-24-001773 · form4-01242024_060101.xml · derivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,586

Underlying: Common Stock · 66,586 shares

Expires 2034-01-21

F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.

Read SEC document
December 06, 2023 Filed Dec 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 6,853 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-015986 · form4-12072023_061201.xml · derivative · entry 7

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,346

Underlying: Common Stock · 6,853 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
December 06, 2023 Filed Dec 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,019 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-015986 · form4-12072023_061201.xml · derivative · entry 6

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,294

Underlying: Common Stock · 1,019 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.

Read SEC document
December 06, 2023 Filed Dec 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,506 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-015986 · form4-12072023_061201.xml · derivative · entry 5

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,055

Underlying: Common Stock · 1,506 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F4 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
December 06, 2023 Filed Dec 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 905 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-015986 · form4-12072023_061201.xml · derivative · entry 4

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 906

Underlying: Common Stock · 905 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F3 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
December 06, 2023 Filed Dec 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 10,283 $16.11 $165,628.28
Disclosure

SEC source: 0001415889-23-015986 · form4-12072023_061201.xml · nonDerivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.71 to $16.455, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
December 06, 2023 Filed Dec 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 7,872 $2.14 $16,846.08
Disclosure

SEC source: 0001415889-23-015986 · form4-12072023_061201.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,574

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
December 06, 2023 Filed Dec 7, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 2,411 $1.74 $4,195.14
Disclosure

SEC source: 0001415889-23-015986 · form4-12072023_061201.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,702

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
November 27, 2023 Filed Nov 29, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 9,086 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-015599 · form4-11292023_061101.xml · derivative · entry 7

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,199

Underlying: Common Stock · 9,086 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
November 27, 2023 Filed Nov 29, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,018 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-015599 · form4-11292023_061101.xml · derivative · entry 6

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,313

Underlying: Common Stock · 1,018 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.

Read SEC document
November 27, 2023 Filed Nov 29, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,507 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-015599 · form4-11292023_061101.xml · derivative · entry 5

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,561

Underlying: Common Stock · 1,507 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F4 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
November 27, 2023 Filed Nov 29, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 906 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-015599 · form4-11292023_061101.xml · derivative · entry 4

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,811

Underlying: Common Stock · 906 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F3 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
November 27, 2023 Filed Nov 29, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 12,517 $16.24 $203,237.28
Disclosure

SEC source: 0001415889-23-015599 · form4-11292023_061101.xml · nonDerivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.635 to $16.58, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
November 27, 2023 Filed Nov 29, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 10,104 $2.14 $21,622.56
Disclosure

SEC source: 0001415889-23-015599 · form4-11292023_061101.xml · nonDerivative · entry 2

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,808

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
November 27, 2023 Filed Nov 29, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 2,413 $1.74 $4,198.62
Disclosure

SEC source: 0001415889-23-015599 · form4-11292023_061101.xml · nonDerivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,704

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
November 24, 2023 Filed Nov 27, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 4,619 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-015509 · form4-11272023_061104.xml · derivative · entry 12

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,285

Underlying: Common Stock · 4,619 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F8 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
November 24, 2023 Filed Nov 27, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 371 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-015509 · form4-11272023_061104.xml · derivative · entry 11

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,331

Underlying: Common Stock · 371 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F7 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.

Read SEC document
November 24, 2023 Filed Nov 27, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 70 $16.07 $1,124.59
Disclosure

SEC source: 0001415889-23-015509 · form4-11272023_061104.xml · nonDerivative · entry 6

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.035 to $16.11, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
November 24, 2023 Filed Nov 27, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 4,920 $15.74 $77,423.09
Disclosure

SEC source: 0001415889-23-015509 · form4-11272023_061104.xml · nonDerivative · entry 5

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,361

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.034 to $16.025, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
November 24, 2023 Filed Nov 27, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 4,990 $2.14 $10,678.60
Disclosure

SEC source: 0001415889-23-015509 · form4-11272023_061104.xml · nonDerivative · entry 4

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,281

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

Read SEC document
November 22, 2023 Filed Nov 27, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 6,322 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-015509 · form4-11272023_061104.xml · derivative · entry 10

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 143,904

Underlying: Common Stock · 6,322 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F8 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

Read SEC document
November 22, 2023 Filed Nov 27, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 648 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-23-015509 · form4-11272023_061104.xml · derivative · entry 9

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,702

Underlying: Common Stock · 648 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F7 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.

Read SEC document
November 22, 2023 Filed Nov 27, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,507 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-015509 · form4-11272023_061104.xml · derivative · entry 8

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,068

Underlying: Common Stock · 1,507 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F6 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
November 22, 2023 Filed Nov 27, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 905 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001415889-23-015509 · form4-11272023_061104.xml · derivative · entry 7

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,717

Underlying: Common Stock · 905 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F5 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
November 22, 2023 Filed Nov 27, 2023 18:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 9,382 $15.17 $142,358.72
Disclosure

SEC source: 0001415889-23-015509 · form4-11272023_061104.xml · nonDerivative · entry 3

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,291

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.